Potential new treatment for blood-related cancersMay 20th, 2010 - 5:27 pm ICT by ANI
Washington, May 20 (ANI): In a new clinical trial, scientists have found that SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, is safe and could offer a potential clinical cure for advanced chronic lymphocytic leukemia (CLL).
Cyclin-dependent kinases are enzymatic proteins that are integrally involved in cellular metabolism, renewal and signaling, and are thought to play key roles in the growth of cancers.
The drug did not demonstrate any clinical effect against advanced multiple myeloma, although researchers hope it might still prove to have some benefit against this blood cancer as part of combination therapy.
“No drugs that target this cancer mechanism are on the market today. I am hopeful that larger studies will show that this targeted therapy is useful against a number of advanced B cell malignancies,” said study author Dr. David S. Siegel, Co-Chief, Multiple Myeloma, John Theurer Cancer Center at Hackensack University Medical Center.
Chronic lymphocytic leukemia (CLL) and multiple myeloma are both considered B cell malignancies, as they attack these cells, also known as B lymphocytes.
Both types of blood cancer leave their victims susceptible to infections and other serious complications. While there are treatments for both cancers, there is no cure, and more effective treatments are needed.
The researchers tested the new medication on 37 patients, 19 with CLL and 18 with myeloma. All patients were given SNS-032, and all were aware of what they were taking.
To test both the drug’s safety and the best potential dose, SNS-032 was given intravenously as a “loading” dose - an initially higher dose that is then reduced to a maintenance level - over five minutes.
This was followed by a six-hour infusion given to all patients on a weekly basis for three consecutive weeks.
One patient with CLL had more than a 50 percent reduction in measurable disease, but no improvement in disease markers in the blood.
Another CLL patient had stable disease for four courses of treatment.
For multiple myeloma, two patients had stable disease with treatment and one had normalization of spleen size, which is an indication of a reduction in blood cancer activity.
Looking at blood test results for the patients, the researchers found anti-cancer activity.
The drug appeared to inhibit cyclin-dependent kinases 7 and 9, two of the three enzymatic proteins targeted in this study.
They also caused apoptosis, or cell death, in cancer cells.
“Our study found that this drug is well tolerated and had some clinical effect, but it is important to note that this was a small, very early stage study. Based on these findings, there is justification for additional research, which will show whether this drug has a place in the arsenal of treatments for hematologic malignancies,” said Siegel.
Preclinical studies of SNS-032 demonstrated that the drug inhibited the growth of cancer cells, and induced apoptosis, in B cell malignancies.
The study was published online in the Journal of Clinical Oncology. (ANI)
- Factor boosting leukemia's aggressiveness identified - Oct 23, 2010
- Cancer drugs offer new hope for Crohn's disease and sarcoidosis - Dec 01, 2010
- New drug combo may treat newly diagnosed cancer patients - Dec 10, 2010
- Full genetic blueprint of blood cancer offers new insights - Mar 24, 2011
- Green tea may help treat chronic leukemia - Jun 05, 2010
- New drug shows promise against platinum resistant ovarian cancer - Oct 10, 2010
- New myeloma drug shows promise - Jun 08, 2010
- New approach could reverse liver failure - Aug 06, 2012
- Novel treatment gives hope to lymphoma, leukemia patients - Feb 27, 2010
- Silenced gene may serve as marker for detecting chronic leukemia early - Aug 06, 2009
- Small molecule may deactivate enemy of cancer-fighting p53 - Dec 08, 2010
- New discovery paves way for treatment of incurable blood cancer - Jul 17, 2010
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- New drug shows dramatic results in reducing lung cancer tumours - Jun 23, 2010
Tags: b cell, b lymphocytes, blood cancer, cancer center, cellular metabolism, chronic lymphocytic leukemia, chronic lymphocytic leukemia cll, consecutive weeks, cyclin dependent kinases, david s siegel, enzymatic proteins, hackensack university medical, hackensack university medical center, loading dose, maintenance level, measurable disease, multiple myeloma, siegel co, theurer, university medical center